Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer’s Disease
Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G […]